Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Cognitive Control in PNES
NCT06647056Completed
- Sponsor
- CHU Nîmes
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of psilocybin in psychogenic nonepileptic seizures (PNES), sponsored by CHU Nîmes. Primary endpoint: Emotional distraction in PNES patients at Day 5. Started Dec 2024; status: completed.
02
Drugs
psilocybin
03
Conditions
psychogenic nonepileptic seizures (PNES)
Beyond the preview
Go deeper on NCT06647056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647056.